• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
      • Corporate image
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
        • ENERGI-F703 ENERGI-F701 ENERGI-F711
      • metabolic diseases
        • ENERGI-F702
      • Anti-inflammation
        • ENERGI-F704 ENERGI-F708
      • Diseases related to deficient mitochondrion
        • ENERGI-F705 ENERGI-F707
      • Others
        • ENERGI-F706 ENERGI-F709 ENERGI-F710
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
    • Company
    • Financial information
      • Monthly revenue information
      • Financial report
    • Shareholders
      • Shareholders' Meeting
      • Dividend policy and dividend distribution
      • Public specification
      • Stock price information
      • Corporate briefing
      • Important information
      • Investment service window
      • Links
    • Corporate Governance
      • Member of the board
      • Functional committee
      • Various management measures
      • Internal audit
      • Head of Corporate Governance
    • Corporate social responsibility
      • Performance of corporate responsibility
      • Corporate Integrity Zone
      • Stakeholder
  • Careers

About us

  • >
  • About us
  • >
  • Information
  • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management Team
    • Members
    • Consultants
  • Contact us

Announcement

  • 2020-12-01
    Energenesis Biomedical won the 17th National Innovation Award-Enterprise Innovation Award
  • 2020-11-12
    Energenesis Biomedical (TWO: 6657) was awarded one of the "TOP Wound Care Solution Providers" by MED TECH OUTLOOK.
  • 2020-10-08
    The IND application of ENERGI-F703 for treating venous leg ulcers (VLU) has been approved by TFDA.
  • 2020-09-21
    The Australian patent “Compounds for activating AMPK and the uses thereof.” is granted.
  • 2020-06-24
    The Singapore patent “Compounds for activating AMPK and the uses thereof.” is granted.
  • 2020-05-07
    The Turk patent “Composition for promoting hair growth” is granted
  • 2020-05-07
    The Europe patent “Compounds for activating AMPK and the uses thereof.” is granted.
  • 2020-03-18
    The Korean patent “Compounds for activating AMPK and the uses thereof.” is granted.
  • 2020-03-16
    The phase II trial of ENERGI-F701, the solution for female hair loss treatment has completed the data analysis.
  • 2019-12-17
    The Israeli patent “Compounds for activating AMPK and the uses thereof.” is granted
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 20204 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice